Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 39-6900 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- KLF6 Monoclonal Antibody (9A2)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 9A2
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- -20°C
Submitted references KLF6-SV1 is a new prognostic biomarker in postoperative patients with non-small cell lung cancer.
A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination.
Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury.
Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.
Zhang N, Li Z, Xiao W, Yang F, Gao W, Sun ZG
Cancer management and research 2018;10:3937-3944
Cancer management and research 2018;10:3937-3944
A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination.
Ahronian LG, Zhu LJ, Chen YW, Chu HC, Klimstra DS, Lewis BC
Oncogene 2016 Sep 1;35(35):4653-62
Oncogene 2016 Sep 1;35(35):4653-62
Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury.
Ghiassi-Nejad Z, Hernandez-Gea V, Woodrell C, Lang UE, Dumic K, Kwong A, Friedman SL
Hepatology (Baltimore, Md.) 2013 Feb;57(2):786-96
Hepatology (Baltimore, Md.) 2013 Feb;57(2):786-96
Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.
Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA
Cancer research 2005 Jul 1;65(13):5761-8
Cancer research 2005 Jul 1;65(13):5761-8
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of KLF6 SV1 was done on 70% confluent log phase HeLa cells. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.25% Triton™ X-100 for 10 minutes, and blocked with 5% BSA for 1 hour at room temperature. The cells were labeled with KLF6 SV1 Mouse Monoclonal Antibody (Product # 39-6900) at 1 µg/mL in 1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing nuclear localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of human (C) colonic epithelium and (D) colorectal cancer tissues using Zymed (R) Ms anti-KLF6 sv1 (Product # 39-6900). Image courtesy of Goutham Narla, MD, PhD, Mount Sinai School of Medicine, NY.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Western blot of tissue sections demonstrating KLF6-SV1. Notes: (1) The corresponding normal lung tissue specimen in one patent with pT2N0M0 (contrast). (2-8) Cancer specimen. Abbreviation: KLF6, Kruppel-like factor 6.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Immunohistochemical staining of lung cancer tissue sections demonstrating KLF6-SV1 (original magnification x400). Notes: ( A ) Lung squamous cell carcinoma specimen with high expression of KLF6-SV1. ( B ) Lung squamous cell carcinoma specimen with low expression of KLF6-SV1. ( C ) The corresponding normal lung tissue specimen with no KLF6-SV1 expression (contrast). ( D ) Lung adenocarcinoma specimen with high expression of KLF6-SV1. ( E ) Lung adenocarcinoma specimen with low expression of KLF6-SV1. ( F ) The corresponding normal lung tissue specimen with no KLF6-SV1 expression (contrast). Abbreviation: KLF6, Kruppel-like factor 6.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 (A) Immunoblot of KLF6 in BL185 cells and the BL185-I1 and M1 subpopulations. (B)Immunoblot of KLF6 in human HCC cell lines. The immortalized hepatocyte cellline Thle-2 is used as a control. (C) KLF6 mRNA levels in human HCC specimenswith or without documented vascular invasion. Data are from the Wurmbach Liverdataset in Oncomine 29 . (D)Immunoblot detection of KLF6 knockdown in BL185 cells infected with lentivirusesencoding KLF6-targeting shRNAs. (E) Soft agar colony formation by BL185 cellsfollowing KLF6 knockdown. (F) Transwell migration activity of BL185 cellsfollowing KLF6 knockdown. (G) Immunoblot confirming ectopic expression ofKLF6-SV1. Cells infected with the pBabe-puro vector are used as a control.beta-actin serves as a loading control. (H) Transwell migration activity ofBL185 cells with ectopic KLF6-SV1 expression. Migration activity for BL185 cellsinfected with pBabe-puro is set to 100%. Data are from a representativeexperiment performed in triplicate. Error bars represent standard deviation. *p
